Cargando…

Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques

The common γ-chain cytokine interleukin-15 (IL-15) plays a significant role in regulating innate and adaptive lymphocyte homeostasis and can stimulate anti-tumor activity of leukocytes. We have previously shown that the circulating IL-15 in the plasma is the heterodimeric form (hetIL-15), produced u...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergamaschi, Cristina, Watson, Dionysios C., Valentin, Antonio, Bear, Jenifer, Peer, Cody J., Figg, William D., Felber, Barbara K., Pavlakis, George N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657354/
https://www.ncbi.nlm.nih.gov/pubmed/29402721
http://dx.doi.org/10.1016/j.cyto.2018.01.011
_version_ 1783438785740013568
author Bergamaschi, Cristina
Watson, Dionysios C.
Valentin, Antonio
Bear, Jenifer
Peer, Cody J.
Figg, William D.
Felber, Barbara K.
Pavlakis, George N.
author_facet Bergamaschi, Cristina
Watson, Dionysios C.
Valentin, Antonio
Bear, Jenifer
Peer, Cody J.
Figg, William D.
Felber, Barbara K.
Pavlakis, George N.
author_sort Bergamaschi, Cristina
collection PubMed
description The common γ-chain cytokine interleukin-15 (IL-15) plays a significant role in regulating innate and adaptive lymphocyte homeostasis and can stimulate anti-tumor activity of leukocytes. We have previously shown that the circulating IL-15 in the plasma is the heterodimeric form (hetIL-15), produced upon co-expression of IL-15 and IL-15 Receptor alpha (IL-15Rα) polypeptides in the same cell, heterodimerization of the two chains and secretion. We investigated the pharmacokinetic and pharmacodynamic profile and toxicity of purified human hetIL-15 cytokine upon injection in rhesus macaques. We compared the effects of repeated hetIL-15 administration during a two-week dosing cycle, using different subcutaneous dosing schemata, i.e. fixed doses of 0.5, 5 and 50 μg/kg or a doubling step-dose scheme ranging from 2 to 64 μg/kg. Following a fixed-dose regimen, dose-dependent peak plasma IL-15 levels decreased significantly between the first and last injection. The trough plasma IL-15 levels measured at 48 h after injections were significantly higher after the first dose, compared to subsequent doses. In contrast, following the step-dose regimen, the systemic exposure increased by more than 1 log between the first injection given at 2 μg/kg and the last injection given at 64 μg/kg, and the trough levels were comparable after each injection. Blood lymphocyte cell count, proliferation, and plasma IL-18 levels peaked at day 8 when hetIL-15 was provided at fixed doses, and at the end of the cycle following a step-dose regimen, suggesting that sustained expansion of target cells requires increasing doses of cytokine. Macaques treated with a 50 μg/kg dose showed moderate and transient toxicity, including fever, signs of capillary leak syndrome and renal dysfunction. In contrast, these effects were mild or absent using the step-dose regimen. The results provide a new method of optimal administration of this homeostatic cytokine and may have applications for the delivery of other cytokines.
format Online
Article
Text
id pubmed-6657354
institution National Center for Biotechnology Information
language English
publishDate 2018
record_format MEDLINE/PubMed
spelling pubmed-66573542019-07-25 Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques Bergamaschi, Cristina Watson, Dionysios C. Valentin, Antonio Bear, Jenifer Peer, Cody J. Figg, William D. Felber, Barbara K. Pavlakis, George N. Cytokine Article The common γ-chain cytokine interleukin-15 (IL-15) plays a significant role in regulating innate and adaptive lymphocyte homeostasis and can stimulate anti-tumor activity of leukocytes. We have previously shown that the circulating IL-15 in the plasma is the heterodimeric form (hetIL-15), produced upon co-expression of IL-15 and IL-15 Receptor alpha (IL-15Rα) polypeptides in the same cell, heterodimerization of the two chains and secretion. We investigated the pharmacokinetic and pharmacodynamic profile and toxicity of purified human hetIL-15 cytokine upon injection in rhesus macaques. We compared the effects of repeated hetIL-15 administration during a two-week dosing cycle, using different subcutaneous dosing schemata, i.e. fixed doses of 0.5, 5 and 50 μg/kg or a doubling step-dose scheme ranging from 2 to 64 μg/kg. Following a fixed-dose regimen, dose-dependent peak plasma IL-15 levels decreased significantly between the first and last injection. The trough plasma IL-15 levels measured at 48 h after injections were significantly higher after the first dose, compared to subsequent doses. In contrast, following the step-dose regimen, the systemic exposure increased by more than 1 log between the first injection given at 2 μg/kg and the last injection given at 64 μg/kg, and the trough levels were comparable after each injection. Blood lymphocyte cell count, proliferation, and plasma IL-18 levels peaked at day 8 when hetIL-15 was provided at fixed doses, and at the end of the cycle following a step-dose regimen, suggesting that sustained expansion of target cells requires increasing doses of cytokine. Macaques treated with a 50 μg/kg dose showed moderate and transient toxicity, including fever, signs of capillary leak syndrome and renal dysfunction. In contrast, these effects were mild or absent using the step-dose regimen. The results provide a new method of optimal administration of this homeostatic cytokine and may have applications for the delivery of other cytokines. 2018-05-07 2018-08 /pmc/articles/PMC6657354/ /pubmed/29402721 http://dx.doi.org/10.1016/j.cyto.2018.01.011 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Article
Bergamaschi, Cristina
Watson, Dionysios C.
Valentin, Antonio
Bear, Jenifer
Peer, Cody J.
Figg, William D.
Felber, Barbara K.
Pavlakis, George N.
Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques
title Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques
title_full Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques
title_fullStr Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques
title_full_unstemmed Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques
title_short Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques
title_sort optimized administration of hetil-15 expands lymphocytes and minimizes toxicity in rhesus macaques
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657354/
https://www.ncbi.nlm.nih.gov/pubmed/29402721
http://dx.doi.org/10.1016/j.cyto.2018.01.011
work_keys_str_mv AT bergamaschicristina optimizedadministrationofhetil15expandslymphocytesandminimizestoxicityinrhesusmacaques
AT watsondionysiosc optimizedadministrationofhetil15expandslymphocytesandminimizestoxicityinrhesusmacaques
AT valentinantonio optimizedadministrationofhetil15expandslymphocytesandminimizestoxicityinrhesusmacaques
AT bearjenifer optimizedadministrationofhetil15expandslymphocytesandminimizestoxicityinrhesusmacaques
AT peercodyj optimizedadministrationofhetil15expandslymphocytesandminimizestoxicityinrhesusmacaques
AT figgwilliamd optimizedadministrationofhetil15expandslymphocytesandminimizestoxicityinrhesusmacaques
AT felberbarbarak optimizedadministrationofhetil15expandslymphocytesandminimizestoxicityinrhesusmacaques
AT pavlakisgeorgen optimizedadministrationofhetil15expandslymphocytesandminimizestoxicityinrhesusmacaques